The DOI matches its Crossref record; 137 of the 139 references it cites were found in a registry or an index.
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Open accessAbstract
As adeno-associated virus (AAV)-based gene therapies are being increasingly approved for use in humans, it is important that we understand vector-host interactions in detail. With the advances in genome-wide genetic screening tools, a clear picture of AAV-host interactions is beginning to emerge. Understanding these interactions can provide insights into the viral life cycle. Accordingly, novel strategies to circumvent the current limitations of AAV-based vectors may be explored. Here, we summarize our current understanding of the various stages in the journey of the vector from the cell surface to the nucleus and contextualize the roles of recently identified host factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After endosomal escape, rAAV particles either enter the nucleus for transgene expression, or become ubiquitylated then degraded by proteasome (84).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [84]
In the citing paper
“However, endosomal acidification is essential for rAAV escape (84), and hydroxychloroquine increases endosomal and lysosomal pH (60), this effect may not be replicated or consistent with systemic application.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [84]
Citations
Cites
Huotari, J., & Helenius, A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.286 · Cited by 2,448
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,409
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Real-Time Single-Molecule Imaging of the Infection Pathway of an Adeno-Associated Virus
Seisenberger, G., Ried, M. U., Endreß, T., Büning, H., Hallek, M. J., & Bräuchle, C. (2001) · Science · doi:10.1126/science.1064103 · Cited by 819
Flagged first, then by citations
2 of the 139 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–122 of 122
Yamamoto, H., Tamari, M., Wada, S., Takahashi, H., Yoshida-Komiya, H., Saito, H., Morita, H., Matsumoto, K., & Motomura, K. (2026) · Placenta · doi:10.1016/j.placenta.2026.01.005
Yoon, S., & Liang, G. (2026) · Research Square · doi:10.21203/rs.3.rs-8426890/v1
Assessing the biopotency of the rAAV9 vector In Vitro
Adhikari, P., Nichols, P. G., Vorobiov, S., Bobo, T. A., & Fu, H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341451
“Notably, the presence of the vector genome in the transduced cells does not necessarily ensure expression of the transgene product [26].”
Kalomoiri, M., Sorini, C., Vos, S. V. T., Camargo, A., Tsalikou, A., Krstic, A., Prakash, C. R., Svenningsson, P., Needhamsen, M., Kakhki, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708277
Mole, A. J., Sander, C. F., Parmar, A., Williams, A. J., Azzouz, M., Hautbergue, G. M., Shaw, P. J., Ferraiuolo, L., & Mead, R. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-38039-z · Cited by 1
“The mechanisms of AAV transduction have been reviewed previously, with N-linked galactose described as the primary receptor for AAV9 along with binding of a putative integrin and laminin receptors as co-receptors 65–67 .”
Swine reporter model for preclinical evaluation and characterization of gene delivery vectors
Campbell, J. M., Korpela, D. M., Han, H., Zhao, S., Webster, D. A., Nguyen, Y. A. H., Koes, N., Aune, R., Dagan, H., Milliken, R., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201729
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
A High-Throughput Automation Platform for Accelerated AAV Stability Optimization
Li, S., Wang, X., Zhi, L., Shameem, M., & Liu, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050608
Hou, Z., & Zhang, P. (2026) · Annual Review of Virology · doi:10.1146/annurev-virology-100424-125355
Enhancing adeno-associated virus cellular entry through receptor engineeringPreprint
Dhungel, B. P., Nagarajah, R., Metierre, C., Yue, F., Kaiser, V., Bazley, H., Curry, C., Gokal, D., Sherman, A., Su, Q. P. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.26.727777
“AAV is internalized via receptor-mediated endocytosis followed by intracellular trafficking through the endosomes and Golgi to the nucleus 7 .”
InfluentialSelf-citationIntracellular trafficking and nuclear compartmentalization of AAV gene delivery
Hutchinson, T. E., Singh, R. E., Oliver, J. Y., Davis, A., Potter, M., Hsi, J., Mietzsch, M., Bennett, A. D., & McKenna, R. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201770
“73 It is not clear if the genome is ejected (loss of packaged genome) at this site, but it does confirm nuclear accumulation of assembled AAV2 capsids at a site where the DNA is actively transcribing.”
Qin, X., Hou, S., Sun, Z., Xu, G., Huo, Y., Luo, Y., Liang, C., & Wang, J. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100012
Olarewaju, O., Bentler, M., Breuer, J., Alioglu, F., Grabowski, A., Prosche, A., Sami, H., Ogris, M., & Büning, H. (2026) · Human Gene Therapy · doi:10.1177/10430342261465461
“24 Endosomal maturation is accompanied by acidi fi cation and activation of endosomal enzymes such as cathepsin B and L, which prime the cap-sids for the latter uncoating step.”
Milagros, S., Pérez‐Martínez, D., Salazar-Diaz, S., de Erenchun, P. R.-R., Nicolao, M., Carte, B., Méndez, M., Echevarria, B., Reichardt, N., & Aldabe, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10369568/v1
Ossi, L., Delfino, S., Marie, H., Schulte, M. M., & Sponchioni, M. (2026) · Biotechnology Journal · doi:10.1002/biot.70295
“Such sequences can play different functions, from the replacement of faulty genes with functional ones, the introduction of sequences originally absent in the patient’s DNA, to even the silencing of improper ones [2–4].”
Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV
Gomes, C. M., Silva, G., Aleixo, M. M., Gomes, M., Simão, D. F., Holtkamp, S., Lobo, D. D., Harish, P., Jenkins, R., Dahal, L. N., et al. (2026) · Advanced Science · doi:10.1002/advs.202520408
Alternative bipartite arrangements of VP1 BR1-3 drive efficient nuclear import of AAV2 capsids
Hoad, M., Nematollahzadeh, S., Cimichella, D., Pavan, S., Pierri, C. L., Roby, J. A., Alvisi, G., & Forwood, J. K. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113562
“Over the years, extensive research has examined the mechanisms by which AAVs enter cells and traffic through the cytoplasm to the nucleus (25).”
Alluvial filtration as a scalable and safe single-use technology for the harvest of viral vectors
Wiesner, J., Bauer, A., & Eisenkraetzer, D. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-14035-1
“…vector-based approaches for gene delivery (Li et al. 2023), recombinant adeno-associated viral (rAAV) vectors have emerged as the preferred vehicles (Issa et al. 2023; Srivastava et al. 2021; Dhungel et al. 2021) making several rAAV vector-based therapeutics available today (Mendell et al. 2021).”
Gene Therapy for Osteoarthritis: Viral and Non-Viral Delivery Strategies
Zhang, M., Mohess, J., Cheung, J., Du, Q., Qiu, J., & Wang, J. (2026) · Viruses · doi:10.3390/v18101151
“Following cellular entry, the rAAV genome is transported to the nucleus, where it is converted into double-stranded DNA (dsDNA) and predominantly persists as episomal concatemers, enabling sustained expression without efficient integration into the host genome [17].”
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Metadata
- Authors
- Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Rasko, John E.J.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 27
- Issue
- 2
- Pages
- 172-184
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W3092811898
- Cited by
- 122
- References
- 139
- Citations by year
- 2026: 32 · 2025: 29 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 14
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Trends in Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NSW Health
- National Health and Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, adeno-associated virus vectors, gene therapy, vector-host interactions, viral life cycle, host factors, nuclear translocation, viral transduction, genome-wide screen
- MeSH terms
- Host Microbial Interactions, Dependovirus, Animals, Biological Transport, Genetic Vectors, Humans, Transduction, Genetic, Genetic Therapy, Gene Transfer Techniques, Cell Tracking
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
